The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Pharmacovigilance: methods, recent developments and future perspectives
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Under-Reporting of Adverse Drug Reactions: A Systematic Review
Hazell, L., & Shakir, S. A. W. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00003 · Cited by 1,931
THALIDOMIDE AND CONGENITAL ABNORMALITIES
Mcbride, W. G. (1961) · The Lancet · doi:10.1016/s0140-6736(61)90927-8 · Cited by 1,141
The Risk Associated with Aprotinin in Cardiac Surgery
Mangano, D. T., Tudor, I. C., & Dietzel, C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051379 · Cited by 1,099
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials
Heiat, A., Gross, C. P., & Krumholz, H. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1682 · Cited by 723 · cited 1×
“This is especially true for the elderly, for women or for people belonging to a minority ethnic group [30, 31].”
BackgroundSzarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Failing the Public Health — Rofecoxib, Merck, and the FDA
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048286 · Cited by 599
The General Practice Research Database: Role in Pharmacovigilance
Wood, L., & Martinez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 331
Genetic susceptibility to adverse drug reactions
Pirmohamed, M., & Park, B. K. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01717-x · Cited by 328
Ellison, D. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92099-x · Cited by 308
The role of data mining in pharmacovigilance
Hauben, M., Madigan, D., Gerrits, C. M., Walsh, L., & Van Puijenbroek, E. P. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.5.929 · Cited by 276
What have we learnt from Vioxx?
Krumholz, H. M., Ross, J. S., Presler, A. H., & Egilman, D. S. (2007) · BMJ · doi:10.1136/bmj.39024.487720.68 · Cited by 267
Attitudinal survey of voluntary reporting of adverse drug reactions
Eland, Belton, Grootheest, V., Meiners, Rawlins, & Stricker (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00060.x · Cited by 256
The Rosiglitazone Story — Lessons from an FDA Advisory Committee Meeting
Rosen, C. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078167 · Cited by 207
Garbe, E., & Suissa, S. (2005) · Handbook of Epidemiology · doi:10.1007/3-540-26577-5_31 · Cited by 189
Gross, C. P., Mallory, R., Heiat, A., & Krumholz, H. M. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00007 · Cited by 188
Adverse Drug Reaction Reporting by Patients in the Netherlands: Three Years of Experience
de Langen, J., van Hunsel, F., Passier, A., de Jong-van den Berg, L., & van Grootheest, K. (2008) · Drug Safety · doi:10.2165/00002018-200831060-00006 · Cited by 177
(2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00002 · Cited by 172
Pharmacists' role in reporting adverse drug reactions in an international perspective
van Grootheest, K., Olsson, S., Couper, M., & de Jong‐van den Berg, L. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.897 · Cited by 171
Clinical trial registration: transparency is the watchword
Sim, I., Chan, A.-W., Gülmezoglu, A. M., Evans, T., & Pang, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68708-4 · Cited by 165
A Data Mining Approach for Signal Detection and Analysis
Bate, A., Lindquist, M., Edwards, I. R., & Orre, R. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00002 · Cited by 155
van Puijenbroek, E., Diemont, W. L., & van Grootheest, K. (2003) · Drug Safety · doi:10.2165/00002018-200326050-00001 · Cited by 148
A model for the future conduct of pharmacovigilance
WALLER, P. C., & Evans, S. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.773 · Cited by 136
How the US Drug Safety System Should Be Changed
Strom, B. L. (2006) · JAMA · doi:10.1001/jama.295.17.2072 · Cited by 134
Reform of Drug Regulation — Beyond an Independent Drug-Safety Board
Ray, W. A., & Stein, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmsb053432 · Cited by 119
Prescription‐event monitoring—recent progress and future horizons
Mann, R. D. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00774.x · Cited by 114
The FDA and Drug Safety: A Proposal for Sweeping Changes
Furberg, C. D., Levin, A. A., Gross, P. A., Shapiro, R. S., & Strom, B. L. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.18.1938 · Cited by 86
Textbook of Pharmacoepidemiology
Strom, B. L., & Kimmel, S. E. (2006) · Wiley eBooks · doi:10.1002/9781118707999 · Cited by 86
Protecting the Health of the Public — Institute of Medicine Recommendations on Drug Safety
Psaty, B. M., & Burke, S. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068228 · Cited by 84
Zarin, D. A., Young, J. L., & West, J. C. (2004) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-005-0838-9 · Cited by 82
Drug Safety Reform at the FDA — Pendulum Swing or Systematic Improvement?
McClellan, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078057 · Cited by 81
Clarke, A., Deeks, J. J., & Shakir, S. (2006) · Drug Safety · doi:10.2165/00002018-200629020-00008 · Cited by 69
Thalidomide and Congenital Malformations
Munn, J. D. (1962) · The Lancet · doi:10.1016/s0140-6736(62)91251-5 · Cited by 59
Paying for Drug Approvals — Who's Using Whom?
Avorn, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078041 · Cited by 58
Spontaneous reporting—of what? Clinical concerns about drugs
Edwards, I. R. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00000.x · Cited by 57
Cardiovascular safety of rosiglitazone
Krall, R. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60824-1 · Cited by 50
FDA Responds to Institute of Medicine Drug Safety Recommendations—In Part
Psaty, B. M., & Charo, R. A. (2007) · JAMA · doi:10.1001/jama.297.17.1917 · Cited by 48
The UK General Practice Research Database
Gelfand, J. M., Margolis, D. J., & Dattani, H. (2006) · Pharmacoepidemiology · doi:10.1002/9780470059876.ch22 · Cited by 43
PDUFA Reauthorization — Drug Safety's Golden Moment of Opportunity?
Hennessy, S., & Strom, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078048 · Cited by 37
Mackay, F. J. (1998) · Drug Safety · doi:10.2165/00002018-199819050-00002 · Cited by 31
The General Practice Research Database: Now and the Future
Parkinson, J., Davis, S., & van Staa, T. P. (2006) · Wiley eBooks · doi:10.1002/9780470059210.ch27 · Cited by 23
Experts Point to Lessons Learned From Controversy Over Rofecoxib Safety
Hampton, T. (2005) · JAMA · doi:10.1001/jama.293.4.413 · Cited by 21
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Coulter, D. M. (2000) · Pharmacoepidemiology and Drug Safety · doi:10.1002/1099-1557(200007/08)9:4<273::aid-pds512>3.0.co;2-t
Cited by
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Iniciativa STROBE: subsídios para a comunicação de estudos observacionais
Malta, M., Cardoso, L. O., Bastos, F. I., Magnanini, M. M. F., & Silva, C. M. F. P. D. (2010) · Revista de Saúde Pública · doi:10.1590/s0034-89102010000300021 · Cited by 912
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Epidemiology and risk factors for drug allergy
Thong, B. Y., & Tan, T. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03774.x · Cited by 393
Real-world Data for Clinical Evidence Generation in Oncology
Khozin, S., Blumenthal, G. M., & Pazdur, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx187 · Cited by 346
Metadata
- Authors
- Härmark, L., & van Grootheest, A. C.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2008-06-04
- Volume
- 64
- Issue
- 8
- Pages
- 743-752
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2018588587
- Cited by
- 289
- References
- 46
- FWCI
- 25.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.